Overview

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Status:
Withdrawn
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of iloprost for PAH in children who are between the ages of 3 and 18 years old.
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Treatments:
Iloprost